GENINUS Inc. (KOSDAQ:389030)

South Korea flag South Korea · Delayed Price · Currency is KRW
5,180.00
-280.00 (-5.13%)
At close: Apr 28, 2026
242.82%
Market Cap 173.20B
Revenue (ttm) 10.48B
Net Income (ttm) -17.37B
Shares Out 33.44M
EPS (ttm) -521.00
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 878,958
Average Volume 1,006,788
Open 5,460.00
Previous Close 5,460.00
Day's Range 5,090.00 - 5,490.00
52-Week Range 1,460.00 - 6,480.00
Beta 0.40
RSI 47.96
Earnings Date May 15, 2026

About GENINUS

GENINUS Inc., a bioinformation analysis company, engages in the research and development, manufacture, and sale of genome analysis solutions in South Korea, the United States, and Asia. It offers tarhet and biomarker discovery; AI digital pathology; single cell analysis; and spatial and in-situ transcriptomics services; and SPACEINSIGHT, a cutting-edge cloud based integrated analysis platform. It serves hospitals, pharmaceutical companies, and researchers. The company was founded in 2018 and is headquartered in Seoul, South Korea. [Read more]

Industry In Vitro and In Vivo Diagnostic Substances
Founded 2018
Country South Korea
Stock Exchange KOSDAQ
Ticker Symbol 389030
Full Company Profile

Financial Performance

In 2025, GENINUS's revenue was 10.48 billion, an increase of 62.40% compared to the previous year's 6.46 billion. Losses were -17.37 billion, 41.6% more than in 2024.

Financial Statements

News

There is no news available yet.